5 results
PRM-151 is being developed for potential therapeutic use to prevent, treat and reduce fibrosis. This study will provide an assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of PRM-151 after administration of ascending…
PRM-151 is being developed for potential therapeutic uses to prevent, treat, and reduce fibrosis. This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PRM-151 after administration of ascending…
The aim of the current study is to extend the time to develop new disease progression in prostate cancer patients with recurrent disease in the form of limited metastases (<5) and in some cases possibly even cure by adding 6 months of ADT to…
The main objective of this study is to determine whether lowering estrogen and progesterone levels with leuprorelin decreases liver growth rates in pre-menopausal women with severe PLD.Secondary objectives are to assess in these women the effect of…
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 in cohort A and cohort B 13-03-2019: new cohort added (3 cohorts now)